{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:37:24Z","timestamp":1781354244105,"version":"3.54.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00447"],"award-info":[{"award-number":["PI24\/00447"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00302"],"award-info":[{"award-number":["PI21\/00302"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00302"],"award-info":[{"award-number":["PI21\/00302"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018-098885-B-100"],"award-info":[{"award-number":["RTI-2018-098885-B-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018-098885-B-100"],"award-info":[{"award-number":["RTI-2018-098885-B-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018-098885-B-100"],"award-info":[{"award-number":["RTI-2018-098885-B-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-128906OB-I00"],"award-info":[{"award-number":["PID2021-128906OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018-098885-B-100"],"award-info":[{"award-number":["RTI-2018-098885-B-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018-098885-B-100"],"award-info":[{"award-number":["RTI-2018-098885-B-100"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02418-2","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:35:11Z","timestamp":1760085311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice"],"prefix":"10.1186","volume":"23","author":[{"given":"Marta","family":"G\u00f3mez-Almer\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gonzalo-Consuegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodr\u00edguez-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Caba\u00f1as-Cotillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Jim\u00e9nez-Amor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Mach\u00edn-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias B.","family":"Wittwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Dzygiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Grether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-0604","authenticated-orcid":false,"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-3777","authenticated-orcid":false,"given":"Eva","family":"de Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2418_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrneurol.2013.203","volume":"9","author":"A Al-Chalabi","year":"2013","unstructured":"Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617\u201328.","journal-title":"Nat Rev Neurol"},{"key":"2418_CR2","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050200","volume":"16","author":"Z Ali","year":"2023","unstructured":"Ali Z, Godoy-Corchuelo JM, Martins-Bach AB, Garcia-Toledo I, Fern\u00e1ndez-Beltr\u00e1n LC, Nair RR, et al. Mutation in the FUS nuclear localisation signal domain causes neurodevelopmental and systemic metabolic alterations. Dis Model Mech. 2023;16:dmm050200.","journal-title":"Dis Model Mech"},{"key":"2418_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/10600280231172802","volume":"58","author":"A Alqallaf","year":"2024","unstructured":"Alqallaf A, Cates DW, Render KP, Patel KA. Sodium phenylbutyrate and taurursodiol: a new therapeutic option for the treatment of amyotrophic lateral sclerosis. Ann Pharmacother. 2024;58:165\u201373.","journal-title":"Ann Pharmacother"},{"key":"2418_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","volume":"64","author":"FJ Alvarez","year":"2008","unstructured":"Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res. 2008;64:653\u20138.","journal-title":"Pediatr Res"},{"key":"2418_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1476-5381.2010.00729.x","volume":"160","author":"BK Atwood","year":"2010","unstructured":"Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467\u201379.","journal-title":"Br J Pharmacol"},{"key":"2418_CR6","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00213-024-06683-w","volume":"241","author":"K Bala","year":"2024","unstructured":"Bala K, Porel P, Aran KR. Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. Psychopharmacology. 2024;241:1939\u201354.","journal-title":"Psychopharmacology"},{"key":"2418_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30394-6","volume":"18","author":"DR Beers","year":"2019","unstructured":"Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211\u201320.","journal-title":"Lancet Neurol"},{"key":"2418_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41593-023-01323-6","volume":"26","author":"F Berriat","year":"2023","unstructured":"Berriat F, Lobsiger CS, Boill\u00e9e S. The contribution of the peripheral immune system to neurodegeneration. Nat Neurosci. 2023;26:942\u201354.","journal-title":"Nat Neurosci"},{"key":"2418_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","volume":"20","author":"LG Bilsland","year":"2006","unstructured":"Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, et al. Increasing cannabinoid levels by Pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006;20:1003\u20135.","journal-title":"FASEB J"},{"key":"2418_CR10","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.2174\/138161208785740081","volume":"14","author":"LG Bilsland","year":"2008","unstructured":"Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des. 2008;14:2306\u201316.","journal-title":"Curr Pharm Des"},{"key":"2418_CR11","doi-asserted-by":"publisher","first-page":"1401706","DOI":"10.3389\/fnins.2024.1401706","volume":"18","author":"D Bradford","year":"2024","unstructured":"Bradford D, Rodgers KE. Advancements and challenges in amyotrophic lateral sclerosis. Front Neurosci. 2024;18:1401706.","journal-title":"Front Neurosci"},{"key":"2418_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/bph.15148","volume":"178","author":"E Buratti","year":"2021","unstructured":"Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol. 2021;178:1298\u2013315.","journal-title":"Br J Pharmacol"},{"key":"2418_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2018.00712","volume":"9","author":"Z Butti","year":"2019","unstructured":"Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2019;9:712.","journal-title":"Front Genet"},{"key":"2418_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032632","volume":"7","author":"AC Calvo","year":"2012","unstructured":"Calvo AC, Manzano R, Atencia-Cibreiro G, Oliv\u00e1n S, Mu\u00f1oz MJ, Zaragoza P, et al. Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice. PLoS One. 2012;7:e32632.","journal-title":"PLoS One"},{"key":"2418_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1049909110369531","volume":"27","author":"GT Carter","year":"2010","unstructured":"Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care. 2010;27:347\u201356.","journal-title":"Am J Hosp Palliat Care"},{"key":"2418_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2007.09.099","volume":"364","author":"P Cavuoto","year":"2007","unstructured":"Cavuoto P, McAinch AJ, Hatzinikolas G, Janovsk\u00e1 A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun. 2007;364:105\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"2418_CR17","doi-asserted-by":"publisher","first-page":"17913","DOI":"10.1073\/pnas.0804610105","volume":"105","author":"IM Chiu","year":"2008","unstructured":"Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008;105:17913\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR18","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1073\/pnas.1815961116","volume":"116","author":"E Coque","year":"2019","unstructured":"Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci USA. 2019;116:2312\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2418_CR19","doi-asserted-by":"publisher","first-page":"18349","DOI":"10.1038\/s41598-021-97859-3","volume":"11","author":"S Dalle","year":"2021","unstructured":"Dalle S, Koppo K. Cannabinoid receptor 1 expression is higher in muscle of old vs. young males, and increases upon resistance exercise in older adults. Sci Rep. 2021;11:18349.","journal-title":"Sci Rep"},{"key":"2418_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cmet.2012.03.019","volume":"15","author":"S Da Cruz","year":"2012","unstructured":"Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK, et al. Elevated PGC-1\u03b1 activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 2012;15:778\u201386.","journal-title":"Cell Metab"},{"key":"2418_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","volume":"92","author":"EMJ de Boer","year":"2020","unstructured":"de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92:86\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2418_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/B978-0-12-417041-4.00005-9","volume-title":"Cannabinoids in neurologic and mental disease","author":"E de Lago","year":"2015","unstructured":"de Lago E, Moreno-Martet M, Espejo-Porras F, Fern\u00e1ndez-Ruiz J. Endocannabinoids and amyotrophic lateral sclerosis. In: Fattore L, editor. Cannabinoids in neurologic and mental disease. The Netherlands: Elsevier; 2015. pp. 99\u2013124."},{"key":"2418_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.etap.2013.04.007","volume":"36","author":"E de Munck","year":"2013","unstructured":"de Munck E, Mu\u00f1oz-S\u00e1ez E, Miguel BG, Solas MT, Ojeda I, Mart\u00ednez A, et al. \u0392-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking amyotrophic lateral sclerosis (ALS): the first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol. 2013;36:243\u201355.","journal-title":"Environ Toxicol Pharmacol"},{"key":"2418_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1179\/174313208X281235","volume":"30","author":"G Dobrowolny","year":"2008","unstructured":"Dobrowolny G, Aucello M, Molinaro M, Musar\u00f2 A. Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model. Neurol Res. 2008;30:131\u20136.","journal-title":"Neurol Res"},{"key":"2418_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1089\/ars.2017.7054","volume":"28","author":"G Dobrowolny","year":"2018","unstructured":"Dobrowolny G, Martini M, Scicchitano BM, Romanello V, Boncompagni S, Nicoletti C, et al. Muscle expression of SOD1G93A triggers the dismantlement of neuromuscular junction via PKC-Theta. Antioxid Redox Signal. 2018;28:1105\u201319.","journal-title":"Antioxid Redox Signal"},{"key":"2418_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","volume":"10","author":"F Espejo-Porras","year":"2015","unstructured":"Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, Di Marzo V, de Lago E, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol. 2015;10:233\u201344.","journal-title":"J Neuroimmune Pharmacol"},{"key":"2418_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/21678421.2018.1425454","volume":"19","author":"F Espejo-Porras","year":"2018","unstructured":"Espejo-Porras F, Fern\u00e1ndez-Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:377\u201386.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2418_CR28","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/bph.14216","volume":"176","author":"F Espejo-Porras","year":"2019","unstructured":"Espejo-Porras F, Garc\u00eda-Toscano L, Rodr\u00edguez-Cueto C, Santos-Garc\u00eda I, de Lago E, Fernandez-Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br J Pharmacol. 2019;176:1585\u2013600.","journal-title":"Br J Pharmacol"},{"key":"2418_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","volume":"28","author":"J Fern\u00e1ndez-Ruiz","year":"2007","unstructured":"Fern\u00e1ndez-Ruiz J, Romero J, Velasco G, Tol\u00f3n RM, Ramos JA, Guzm\u00e1n M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci. 2007;28:39\u201345.","journal-title":"Trends Pharmacol Sci"},{"key":"2418_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","volume":"12","author":"J Fern\u00e1ndez-Ruiz","year":"2015","unstructured":"Fern\u00e1ndez-Ruiz J, Moro MA, Mart\u00ednez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke\/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015;12:793\u2013806.","journal-title":"Neurotherapeutics"},{"key":"2418_CR31","first-page":"551","volume":"10","author":"M Fern\u00e1ndez-Trapero","year":"2017","unstructured":"Fern\u00e1ndez-Trapero M, Espejo-Porras F, Rodr\u00edguez-Cueto C, Coates JR, P\u00e9rez-D\u00edaz C, de Lago E, et al. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech. 2017;10:551\u20138.","journal-title":"Dis Model Mech"},{"key":"2418_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","volume":"7","author":"L Ferraiuolo","year":"2011","unstructured":"Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:616\u201330.","journal-title":"Nat Rev Neurol"},{"key":"2418_CR33","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1371\/journal.pone.0001205","volume":"2","author":"S Garbuzova-Davis","year":"2007","unstructured":"Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One. 2007a;2:e1205.","journal-title":"PLoS One"},{"key":"2418_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.brainres.2007.04.044","volume":"1157","author":"S Garbuzova-Davis","year":"2007","unstructured":"Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007b;1157:126\u201337.","journal-title":"Brain Res"},{"key":"2418_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fncel.2014.00021","volume":"8","author":"S Garbuzova-Davis","year":"2014","unstructured":"Garbuzova-Davis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.","journal-title":"Front Cell Neurosci"},{"key":"2418_CR36","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00702-020-02213-y","volume":"127","author":"F Geser","year":"2020","unstructured":"Geser F, Fellner L, Haybaeck J, Wenning GK. Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down? J Neural Transm. 2020;127:1097\u2013105.","journal-title":"J Neural Transm"},{"key":"2418_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026757","volume":"8","author":"I Gijselinck","year":"2018","unstructured":"Gijselinck I, Cruts M, Van Broeckhoven C. The genetics of C9orf72 expansions. Cold Spring Harb Perspect Med. 2018;8:a026757.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2418_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105226","volume":"150","author":"W Grabon","year":"2023","unstructured":"Grabon W, Rheims S, Smith J, Bodennec J, Belmeguenai A, Bezin L. CB2 receptor in the CNS: from immune and neuronal modulation to behavior. Neurosci Biobehav Rev. 2023;150:105226.","journal-title":"Neurosci Biobehav Rev"},{"key":"2418_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1517\/14728214.2011.604312","volume":"16","author":"AA Habib","year":"2011","unstructured":"Habib AA, Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs. 2011;16:537\u201358.","journal-title":"Expert Opin Emerg Drugs"},{"key":"2418_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","volume":"7","author":"O Hardiman","year":"2011","unstructured":"Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639\u201349.","journal-title":"Nat Rev Neurol"},{"key":"2418_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-24","volume":"9","author":"S Herdewyn","year":"2014","unstructured":"Herdewyn S, Cirillo C, Van Den Bosch L, Robberecht W, Vanden Berghe P, Van Damme P. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol Neurodegener. 2014;9:24.","journal-title":"Mol Neurodegener"},{"key":"2418_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12974-019-1589-y","volume":"16","author":"JH Jara","year":"2019","unstructured":"Jara JH, Gautam M, Kocak N, Xie EF, Mao Q, Bigio EH, et al. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J Neuroinflammation. 2019;16:196.","journal-title":"J Neuroinflammation"},{"key":"2418_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gene.2015.11.049","volume":"577","author":"SJ Kaur","year":"2016","unstructured":"Kaur SJ, McKeown SR, Rashid S. Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene. 2016;577:109\u201318.","journal-title":"Gene"},{"key":"2418_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","volume":"542","author":"K Kim","year":"2006","unstructured":"Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100\u20135.","journal-title":"Eur J Pharmacol"},{"key":"2418_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/jpm10030101","volume":"10","author":"L Le Gall","year":"2020","unstructured":"Le Gall L, Anakor E, Connolly O, Vijayakumar UG, Duddy WJ, Duguez S. Molecular and cellular mechanisms affected in ALS. J Pers Med. 2020;10:101.","journal-title":"J Pers Med"},{"key":"2418_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bpa.12350","volume":"26","author":"JP Loeffler","year":"2016","unstructured":"Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol. 2016;26:227\u201336.","journal-title":"Brain Pathol"},{"key":"2418_CR47","doi-asserted-by":"publisher","first-page":"12251","DOI":"10.1038\/s41598-021-91094-6","volume":"11","author":"A Mejia Maza","year":"2021","unstructured":"Mejia Maza A, Jarvis S, Lee WC, Cunningham TJ, Schiavo G, Secrier M, et al. NMJ-analyser identifies subtle early changes in mouse models of neuromuscular disease. Sci Rep. 2021;11:12251.","journal-title":"Sci Rep"},{"key":"2418_CR48","doi-asserted-by":"publisher","first-page":"19546","DOI":"10.1073\/pnas.0609411103","volume":"103","author":"TM Miller","year":"2006","unstructured":"Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2006;103:19546\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12035-020-02148-1","volume":"58","author":"R Moreno-Luna","year":"2021","unstructured":"Moreno-Luna R, Esteban PF, Paniagua-Torija B, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E. Heterogeneity of the endocannabinoid system between cerebral cortex and spinal cord oligodendrocytes. Mol Neurobiol. 2021;58:689\u2013702.","journal-title":"Mol Neurobiol"},{"key":"2418_CR50","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/cns.12262","volume":"20","author":"M Moreno-Martet","year":"2014","unstructured":"Moreno-Martet M, Espejo-Porras F, Fern\u00e1ndez-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex\u00ae-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20:809\u201315.","journal-title":"CNS Neurosci Ther"},{"key":"2418_CR51","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798697","volume":"37","author":"N Ouali Alami","year":"2018","unstructured":"Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, et al. NF-\u03baB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37:e98697.","journal-title":"EMBO J"},{"key":"2418_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neuropharm.2017.03.037","volume":"124","author":"N Pasquarelli","year":"2017","unstructured":"Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, Bayer H, et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology. 2017;124:157\u201369.","journal-title":"Neuropharmacology"},{"key":"2418_CR53","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41593-019-0498-9","volume":"22","author":"G Picchiarelli","year":"2019","unstructured":"Picchiarelli G, Demestre M, Zuko A, Been M, Higelin J, Dieterl\u00e9 S, et al. FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat Neurosci. 2019;22:1793\u2013805.","journal-title":"Nat Neurosci"},{"key":"2418_CR54","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.3390\/molecules24183338","volume":"24","author":"RF Porter","year":"2019","unstructured":"Porter RF, Szczesniak AM, Toguri JT, Gebremeskel S, Johnston B, Lehmann C, et al. Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis. Molecules. 2019;24:3338.","journal-title":"Molecules"},{"key":"2418_CR55","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.3390\/molecules29143381","volume":"29","author":"V Rakotoarivelo","year":"2024","unstructured":"Rakotoarivelo V, Mayer TZ, Simard M, Flamand N, Di Marzo V. The impact of the CB2 cannabinoid receptor in inflammatory diseases: an update. Molecules. 2024;29:3381.","journal-title":"Molecules"},{"key":"2418_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14660820310016813","volume":"5","author":"C Raman","year":"2004","unstructured":"Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:33\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2418_CR57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Sim\u00f3n-S\u00e1nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron"},{"key":"2418_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","volume":"17","author":"AE Renton","year":"2014","unstructured":"Renton AE, Chi\u00f2 A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17\u201323.","journal-title":"Nat Neurosci"},{"key":"2418_CR59","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1073\/pnas.92.3.689","volume":"92","author":"ME Ripps","year":"1995","unstructured":"Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 1995;92:689\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR60","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bph.15386","volume":"178","author":"C Rodr\u00edguez-Cueto","year":"2021","unstructured":"Rodr\u00edguez-Cueto C, Garc\u00eda-Toscano L, Santos-Garc\u00eda I, G\u00f3mez-Almer\u00eda M, Gonzalo-Consuegra C, Espejo-Porras F, et al. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Br J Pharmacol. 2021a;178:1373\u201387.","journal-title":"Br J Pharmacol"},{"key":"2418_CR61","doi-asserted-by":"publisher","first-page":"e12972","DOI":"10.1111\/bpa.12972","volume":"31","author":"C Rodr\u00edguez-Cueto","year":"2021","unstructured":"Rodr\u00edguez-Cueto C, G\u00f3mez-Almer\u00eda M, Garc\u00eda-Toscano L, Romero J, Hillard CJ, de Lago E, Fern\u00e1ndez-Ruiz J. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 Transgenic mice, a model of amyotrophic lateral sclerosis. Brain Pathol. 2021b;31:e12972.","journal-title":"Brain Pathol"},{"key":"2418_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bcp.2018.07.049","volume":"157","author":"C Rodr\u00edguez-Cueto","year":"2018","unstructured":"Rodr\u00edguez-Cueto C, Santos-Garc\u00eda I, Garc\u00eda-Toscano L, Espejo-Porras F, Bellido M, Fern\u00e1ndez-Ruiz J, et al. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem Pharmacol. 2018;157:217\u201326.","journal-title":"Biochem Pharmacol"},{"key":"2418_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in cu\/zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59\u201362.","journal-title":"Nature"},{"key":"2418_CR64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.expneurol.2010.03.030","volume":"224","author":"S Rossi","year":"2010","unstructured":"Rossi S, Bernardi G, Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol. 2010;224:92\u2013102.","journal-title":"Exp Neurol"},{"key":"2418_CR65","first-page":"7","volume":"68","author":"JD Rothstein","year":"1995","unstructured":"Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol. 1995;68:7\u201320.","journal-title":"Adv Neurol"},{"key":"2418_CR66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","volume":"171","author":"JD Rothstein","year":"2017","unstructured":"Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171:725.","journal-title":"Cell"},{"key":"2418_CR67","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.3390\/cimb46080465","volume":"46","author":"M Sacharczuk","year":"2024","unstructured":"Sacharczuk M, Mickael ME, Kubick N, Kami\u0144ska A, Horba\u0144czuk JO, Atanasov AG, et al. The current landscape of hypotheses describing the contribution of CD4\u2009+\u2009heterogeneous populations to ALS. Curr Issues Mol Biol. 2024;46:7846\u201361.","journal-title":"Curr Issues Mol Biol"},{"key":"2418_CR68","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamaneurol.2018.0035","volume":"75","author":"RK Sheean","year":"2018","unstructured":"Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681\u20139.","journal-title":"JAMA Neurol"},{"key":"2418_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3193","volume":"9","author":"M Shimizu","year":"2023","unstructured":"Shimizu M, Shiraishi N, Tada S, Sasaki T, Beck G, Nagano S, et al. RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS. Sci Adv. 2023;9:eadg3193.","journal-title":"Sci Adv"},{"key":"2418_CR70","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","volume":"101","author":"JL Shoemaker","year":"2007","unstructured":"Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87\u201398.","journal-title":"J Neurochem"},{"key":"2418_CR71","doi-asserted-by":"publisher","first-page":"826400","DOI":"10.3389\/fphar.2022.826400","volume":"13","author":"M Simard","year":"2022","unstructured":"Simard M, Rakotoarivelo V, Di Marzo V, Flamand N. Expression and functions of the CB2 receptor in human leukocytes. Front Pharmacol. 2022;13:826400.","journal-title":"Front Pharmacol"},{"key":"2418_CR72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","volume":"138","author":"EO Talbott","year":"2016","unstructured":"Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225\u201338.","journal-title":"Handb Clin Neurol"},{"key":"2418_CR73","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/mt.2008.73","volume":"16","author":"C Towne","year":"2008","unstructured":"Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther. 2008;16:1018\u201325.","journal-title":"Mol Ther"},{"key":"2418_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.brainres.2012.04.031","volume":"1462","author":"W Tsao","year":"2012","unstructured":"Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, et al. Rodent models of TDP-43: recent advances. Brain Res. 2012;1462:26\u201339.","journal-title":"Brain Res"},{"key":"2418_CR75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1242\/dmm.029058","volume":"10","author":"P Van Damme","year":"2017","unstructured":"Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10:537\u201349.","journal-title":"Dis Model Mech"},{"key":"2418_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13311-016-0503-x","volume":"14","author":"LT Vu","year":"2017","unstructured":"Vu LT, Bowser R. Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:119\u201334.","journal-title":"Neurotherapeutics"},{"key":"2418_CR77","doi-asserted-by":"publisher","first-page":"18809","DOI":"10.1073\/pnas.0908767106","volume":"106","author":"I Wegorzewska","year":"2009","unstructured":"Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR78","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000321547","volume":"8","author":"I Wegorzewska","year":"2011","unstructured":"Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2011;8:262\u201374.","journal-title":"Neurodegener Dis"},{"key":"2418_CR79","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/14660820510030149","volume":"6","author":"P Weydt","year":"2005","unstructured":"Weydt P, Hong S, Witting A, M\u00f6ller T, Stella N, Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:182\u20134.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"2418_CR80","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-012-1039-8","volume":"125","author":"EA Winkler","year":"2013","unstructured":"Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111\u201320.","journal-title":"Acta Neuropathol"},{"key":"2418_CR81","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/hmg\/ddq106","volume":"19","author":"M Wong","year":"2010","unstructured":"Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet. 2010;19:2284\u2013302.","journal-title":"Hum Mol Genet"},{"key":"2418_CR82","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnmol.2020.00078","volume":"13","author":"YC Xue","year":"2020","unstructured":"Xue YC, Ng CS, Xiang P, Liu H, Zhang K, Mohamud Y, et al. Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. Front Mol Neurosci. 2020;13:78.","journal-title":"Front Mol Neurosci"},{"key":"2418_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-6-12","volume":"6","author":"Y Yiangou","year":"2006","unstructured":"Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.","journal-title":"BMC Neurol"},{"key":"2418_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12974-023-03007-1","volume":"21","author":"S Zaccai","year":"2024","unstructured":"Zaccai S, Nemirovsky A, Lerner L, Alfahel L, Eremenko E, Israelson A, et al. CD4 t-cell aging exacerbates neuroinflammation in a late-onset mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2024;21:17.","journal-title":"J Neuroinflammation"},{"key":"2418_CR85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lfs.2019.05.056","volume":"230","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zhang M, Wang L, Yu T, Jiang S, Jiang P, et al. Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Life Sci. 2019;230:55\u201367.","journal-title":"Life Sci"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02418-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:25:50Z","timestamp":1760365550000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02418-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02418-2","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were carried out in laboratory animals and were conducted according to local and European rules (directive 2010\/63\/EU) following the ARRIVE guidelines. All animal experiments were approved by the ethical committees of our university and the regulatory institution (PROEX 201.8\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"427"}}